Trastuzumab Rezetecan Shows Promise in HER2-Expressing GI CancersByErin DoranMarch 24th 2026Phase 1 data show HER2 ADC trastuzumab rezetecan drives responses in advanced gastric/GEJ and colorectal cancers with manageable safety and low ILD.